SCHEMBL10102735

SCHEMBL10102735

CN(C)c1ccc(C(=O)Nc2ccc(CCCC(=O)O)cc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.70
MAPT P10636 5/20 0.62
ALDH1A1 P00352 4/20 0.62
RAB9A P51151 3/20 0.62
MCL1 Q07820 3/20 0.62
NPC1 O15118 2/20 0.62
NFKB1 P19838 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
ALOX15 P16050 1/20 0.62
MAPK1 P28482 1/20 0.62
NFKB2 Q00653 1/20 0.62
RELA Q04206 1/20 0.62
KDM4E B2RXH2 5/20 0.58
GALR3 O60755 1/20 0.58
TRPV1 Q8NER1 1/20 0.56
HSD17B10 Q99714 3/20 0.53
LMNA P02545 2/20 0.53
TP53 P04637 1/20 0.53
TSHR P16473 2/20 0.53
KCNK3 O14649 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14088989 0.89 NR1H4 (0.81) NR1H4RAB9ANPC1SMN1; SMN2MAPK1
SCHEMBL1468045 0.85 NR1H4 (0.58) NR1H4MAPTALDH1A1RAB9AMCL1
SCHEMBL472311 0.84 ALDH1A1 (0.61) NR1H4MAPTALDH1A1RAB9AMCL1
SCHEMBL28134761 0.83 NR1H4 (0.73) NR1H4KDM4ETRPV1HSD17B10HDAC1
SCHEMBL10102714 0.83 NR1H4 (0.72) NR1H4RAB9ANPC1SMN1; SMN2MAPK1
SCHEMBL2061403 0.82 NR1H4 (0.71) NR1H4SMN1; SMN2MAPK1KDM4ETRPV1
SCHEMBL13814817 0.82 NR1H4 (0.71) NR1H4MAPTNPC1KDM4ETRPV1
SCHEMBL1468708 0.82 ALDH1A1 (0.53) NR1H4MAPTALDH1A1RAB9AMCL1
SCHEMBL27193216 0.82 HDAC1 (0.71) MAPTALDH1A1RAB9AMCL1NPC1
SCHEMBL12528011 0.80 RAB9A (0.64) MAPTALDH1A1RAB9AMCL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2409569-B1 Method for administering GLP-1 molecules EMISPHERE TECH INC (US) 2017-08-16 EP disclosed
EP-1478233-B1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECH INC (US) 2016-11-09 EP disclosed
US-9345722-B2 Pharmaceutical formulations for the treatment of alzheimer's disease EMISPHERE TECHNOLOGIES, INC. (US) 2016-05-24 US disclosed
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2015-07-23 US disclosed
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2015-07-23 US disclosed
US-8492330-B2 Formulation comprising GLP-1 EMISPHERE TECHNOLOGIES, INC. (US) 2013-07-23 US disclosed
US-8492330-B2 Formulation comprising GLP-1 EMISPHERE TECHNOLOGIES, INC. (US) 2013-07-23 US disclosed
EP-2409569-A2 Method for administering GLP-1 molecules Emisphere Technologies, Inc. (US) 2012-01-25 EP disclosed
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECHNOLOGIES, INC. (US) 2011-07-21 US disclosed
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECHNOLOGIES, INC. (US) 2011-07-21 US disclosed
US-7939494-B2 Method for administering GLP-1 molecules EMISPHERE TECHNOLOGIES, INC. (US) 2011-05-10 US disclosed
US-7939494-B2 Method for administering GLP-1 molecules EMISPHERE TECHNOLOGIES, INC. (US) 2011-05-10 US disclosed
US-20100004310-A1 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE EMISPHERE TECHNOLOGIES INC. (US) 2010-01-07 US disclosed
US-20090286735-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2009-11-19 US disclosed
US-20090286735-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2009-11-19 US disclosed
WO-2008014232-A2 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE EMISPHERE TECHNOLOGIES, INC. (US) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 NR1H4 271/4885MAPT 4362/4885ALDH1A1 3386/4885
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 NR1H4 271/4885MAPT 4362/4885ALDH1A1 3386/4885
US-20090286735-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 NR1H4 271/4885MAPT 4362/4885ALDH1A1 3386/4885
US-20100004310-A1 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE PSEN1, PSEN2, APP NR1H4 1072/4885MAPT 4/4885ALDH1A1 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.